Genetic Interstitial Lung Disease

Clinics in Chest Medicine

Volumn 33, Issue 1, 2012, Pages 95-110

  Devine, Megan Stuebner ^a   Garcia, Christine Kim ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Genetics; Interstitial lung disease; Mutations; Pulmonary fibrosis

Indexed keywords

COLLAGEN; DNA; FIBRONECTIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; LAMININ; NUCLEOPROTEIN; SURFACTANT PROTEIN B;

BIRT HOGG DUBE SYNDROME; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DISEASE ASSOCIATION; DISEASE COURSE; DNA REPLICATION; DYSKERATOSIS CONGENITA; DYSPNEA; FAMILIAL ADULT ONSET PULMONARY FIBROSIS; FAMILIAL PULMONARY ALVEOLAR MICROLITHIASIS; FAMILIAL PULMONARY FIBROSIS ASSOCIATED WITH TELOMERASE MUTATION; GAUCHER DISEASE; GENE INTERACTION; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC SCREENING; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYPER-IMMUNOGLOBULIN E SYNDROME; IMMUNOGLOBULIN DEFICIENCY; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG FIBROSIS; LUNG INFILTRATE; LUNG SARCOIDOSIS; LYMPHANGIOLEIOMYOMATOSIS; LYSINURIC PROTEIN INTOLERANCE; NEUROFIBROMATOSIS; NIEMANN PICK DISEASE; OCULAR ALBINISM; PATHOGENESIS; PNEUMATOCELE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SURFACTANT METABOLISM DYSFUNCTION TYPE 1; SURFACTANT METABOLISM DYSFUNCTION TYPE 2; SURFACTANT METABOLISM DYSFUNCTION TYPE 3; SURFACTANT METABOLISM DYSFUNCTION TYPE 4; SURFACTANT PROTEIN B DEFICIENCY; SURFACTANT PROTEIN C DEFICIENCY; THORAX RADIOGRAPHY; TUBEROUS SCLEROSIS;

ADULT; BIRT-HOGG-DUBE SYNDROME; CALCINOSIS; FEMALE; GENETIC DISEASES, INBORN; GENETIC DISEASES, X-LINKED; HETEROZYGOTE; HUMANS; INDEL MUTATION; KIDNEY NEOPLASMS; LUNG DISEASES; LUNG DISEASES, INTERSTITIAL; MUTATION; PEDIGREE; PNEUMOTHORAX; PROTO-ONCOGENE PROTEINS; PULMONARY ALVEOLAR PROTEINOSIS; PULMONARY FIBROSIS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN B; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RECURRENCE; RNA; SARCOIDOSIS, PULMONARY; SIBLINGS; TELOMERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84857437841     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2011.11.001     Document Type: Review

References (151)

1. Drachtman R.A., Alter B.P. Dyskeratosis congenita. Dermatol Clin 1995, 13(1):33-39.
2. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 2000, 110(4):768-779.
3. Calado R.T., Young N.S. Telomere diseases. N Engl J Med 2009, 361(24):2353-2365.
4. Lee H.W., Blasco M.A., Gottlieb G.J., et al. Essential role of mouse telomerase in highly proliferative organs. Nature 1998, 392(6676):569-574.
5. Vulliamy T., Marrone A., Szydlo R., et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 2004, 36(5):447-449.
6. Armanios M., Chen J.L., Chang Y.P., et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 2005, 102(44):15960-15964.
7. Paul S.R., Perez-Atayde A., Williams D.A. Interstitial pulmonary disease associated with dyskeratosis congenita. Am J Pediatr Hematol Oncol 1992, 14(1):89-92.
8. Verra F., Kouzan S., Saiag P., et al. Bronchoalveolar disease in dyskeratosis congenita. Eur Respir J 1992, 5(4):497-499.
9. Yabe M., Yabe H., Hattori K., et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 1997, 19(4):389-392.
10. Rocha V., Devergie A., Socie G., et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998, 103(1):243-248.
11. Giri N., Lee R., Faro A., et al. Lung transplantation for pulmonary fibrosis in dyskeratosis congenita: case report and systematic literature review. BMC Blood Disord 2011, 11(1):3.
12. Cohen S.B., Graham M.E., Lovrecz G.O., et al. Protein composition of catalytically active human telomerase from immortal cells. Science 2007, 315(5820):1850-1853.
13. Parry E.M., Alder J.K., Lee S.S., et al. Decreased dyskerin levels as a mechanism of telomere shortening in X-linked dyskeratosis congenita. J Med Genet 2011, 48(5):327-333.
14. Safa W.F., Lestringant G.G., Frossard P.M. X-linked dyskeratosis congenita: restrictive pulmonary disease and a novel mutation. Thorax 2001, 56(11):891-894.
15. Marrone A., Sokhal P., Walne A., et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 2007, 92(8):1013-1020.
16. Walne A.J., Vulliamy T., Marrone A., et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 2007, 16(13):1619-1629.
17. Vulliamy T., Beswick R., Kirwan M., et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 2008, 105(23):8073-8078.
18. Zhong F., Savage S.A., Shkreli M., et al. Disruption of telomerase trafficking by TCAB1 mutation causes dyskeratosis congenita. Genes Dev 2011, 25(1):11-16.
19. Burkhalter J.L., Morano J.U., McCay M.B. Diffuse interstitial lung disease in neurofibromatosis. South Med J 1986, 79(8):944-946.
20. Massaro D., Katz S. Fibrosing alveolitis: its occurrence, roentgenographic, and pathologic features in von Recklinghausen's neurofibromatosis. Am Rev Respir Dis 1966, 93(6):934-942.
21. Webb W.R., Goodman P.C. Fibrosing alveolitis in patients with neurofibromatosis. Radiology 1977, 122(2):289-293.
22. Hirsch N.P., Murphy A., Radcliffe J.J. Neurofibromatosis: clinical presentations and anaesthetic implications. Br J Anaesth 2001, 86(4):555-564.
23. Lenoir S., Grenier P., Brauner M.W., et al. Pulmonary lymphangiomyomatosis and tuberous sclerosis: comparison of radiographic and thin-section CT findings. Radiology 1990, 175(2):329-334.
24. Curatolo P., Bombardieri R., Jozwiak S. Tuberous sclerosis. Lancet 2008, 372(9639):657-668.
25. Avila N.A., Dwyer A.J., Rabel A., et al. Sporadic lymphangioleiomyomatosis and tuberous sclerosis complex with lymphangioleiomyomatosis: comparison of CT features. Radiology 2007, 242(1):277-285.
26. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277(5327):805-808.
27. The European Chromosome 16 Tuberous Sclerosis Consortium Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75(7):1305-1315.
28. Henske E.P., Wessner L.L., Golden J., et al. Loss of tuberin in both subependymal giant cell astrocytomas and angiomyolipomas supports a two-hit model for the pathogenesis of tuberous sclerosis tumors. Am J Pathol 1997, 151(6):1639-1647.
29. Carsillo T., Astrinidis A., Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 2000, 97(11):6085-6090.
30. Sato T., Seyama K., Fujii H., et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 2002, 47(1):20-28.
31. Smolarek T.A., Wessner L.L., McCormack F.X., et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998, 62(4):810-815.
32. Bissler J.J., McCormack F.X., Young L.R., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008, 358(2):140-151.
33. Morton J.M., McLean C., Booth S.S., et al. Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment. J Heart Lung Transplant 2008, 27(4):462-465.
34. Krueger D.A., Care M.M., Holland K., et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363(19):1801-1811.
35. McCormack F.X., Inoue Y., Moss J., et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011, 364(17):1595-1606.
36. Toro J.R., Pautler S.E., Stewart L., et al. Lung cysts, spontaneous pneumothorax, and genetic associations in 89 families with Birt-Hogg-Dubé syndrome. Am J Respir Crit Care Med 2007, 175(10):1044-1053.
37. Toro J.R., Wei M.H., Glenn G.M., et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet 2008, 45(6):321-331.
38. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome. Cancer Cell 2002, 2(2):157-164.
39. Painter J.N., Tapanainen H., Somer M., et al. 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet 2005, 76(3):522-527.
40. Graham R.B., Nolasco M., Peterlin B., et al. Nonsense mutations in folliculin presenting as isolated familial spontaneous pneumothorax in adults. Am J Respir Crit Care Med 2005, 172(1):39-44.
41. Agarwal P.P., Gross B.H., Holloway B.J., et al. Thoracic CT findings in Birt-Hogg-Dubé syndrome. AJR Am J Roentgenol 2011, 196(2):349-352.
42. Tobino K., Gunji Y., Kurihara M., et al. Characteristics of pulmonary cysts in Birt-Hogg-Dubé syndrome: thin-section CT findings of the chest in 12 patients. Eur J Radiol 2011, 77(3):403-409.
43. Grimbacher B., Holland S.M., Gallin J.I., et al. Hyper-IgE syndrome with recurrent infections-an autosomal dominant multisystem disorder. N Engl J Med 1999, 340(9):692-702.
44. Grimbacher B., Schaffer A.A., Holland S.M., et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet 1999, 65(3):735-744.
45. Freeman A.F., Holland S.M. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res 2009, 65(5 Pt 2):32R-37R.
46. Freeman A.F., Kleiner D.E., Nadiminti H., et al. Causes of death in hyper-IgE syndrome. J Allergy Clin Immunol 2007, 119(5):1234-1240.
47. Milner J.D., Brenchley J.M., Laurence A., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008, 452(7188):773-776.
48. Minegishi Y., Saito M., Tsuchiya S., et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007, 448(7157):1058-1062.
49. Hermansky F., Pudlak P. Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood 1959, 14(2):162-169.
50. Gahl W.A., Brantly M., Kaiser-Kupfer M.I., et al. Genetic defects and clinical characteristics of patients with a form of oculocutaneous albinism (Hermansky-Pudlak syndrome). N Engl J Med 1998, 338(18):1258-1264.
51. Witkop C.J., Krumwiede M., Sedano H., et al. Reliability of absent platelet dense bodies as a diagnostic criterion for Hermansky-Pudlak syndrome. Am J Hematol 1987, 26(4):305-311.
52. Dell'Angelica E.C., Shotelersuk V., Aguilar R.C., et al. Altered trafficking of lysosomal proteins in Hermansky-Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 1999, 3(1):11-21.
53. Morgan N.V., Pasha S., Johnson C.A., et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet 2006, 78(1):160-166.
54. Martina J.A., Moriyama K., Bonifacino J.S. BLOC-3, a protein complex containing the Hermansky-Pudlak syndrome gene products HPS1 and HPS4. J Biol Chem 2003, 278(31):29376-29384.
55. Suzuki T., Li W., Zhang Q., et al. The gene mutated in cocoa mice, carrying a defect of organelle biogenesis, is a homologue of the human Hermansky-Pudlak syndrome-3 gene. Genomics 2001, 78(1-2):30-37.
56. Zhang Q., Zhao B., Li W., et al. Ru2 and Ru encode mouse orthologs of the genes mutated in human Hermansky-Pudlak syndrome types 5 and 6. Nat Genet 2003, 33(2):145-153.
57. Li W., Zhang Q., Oiso N., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 2003, 35(1):84-89.
58. Wildenberg S.C., Oetting W.S., Almodovar C., et al. A gene causing Hermansky-Pudlak syndrome in a Puerto Rican population maps to chromosome 10q2. Am J Hum Genet 1995, 57(4):755-765.
59. Brantly M., Avila N.A., Shotelersuk V., et al. Pulmonary function and high-resolution CT findings in patients with an inherited form of pulmonary fibrosis, Hermansky-Pudlak syndrome, due to mutations in HPS-1. Chest 2000, 117(1):129-136.
60. Avila N.A., Brantly M., Premkumar A., et al. Hermansky-Pudlak syndrome: radiography and CT of the chest compared with pulmonary function tests and genetic studies. AJR Am J Roentgenol 2002, 179(4):887-892.
61. Anderson P.D., Huizing M., Claassen D.A., et al. Hermansky-Pudlak syndrome type 4 (HPS-4): clinical and molecular characteristics. Hum Genet 2003, 113(1):10-17.
62. Bachli E.B., Brack T., Eppler E., et al. Hermansky-Pudlak syndrome type 4 in a patient from Sri Lanka with pulmonary fibrosis. Am J Med Genet A 2004, 127A(2):201-207.
63. Gahl W.A., Brantly M., Troendle J., et al. Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome. Mol Genet Metab 2002, 76(3):234-242.
64. Nakatani Y., Nakamura N., Sano J., et al. Interstitial pneumonia in Hermansky-Pudlak syndrome: significance of florid foamy swelling/degeneration (giant lamellar body degeneration) of type-2 pneumocytes. Virchows Arch 2000, 437(3):304-313.
65. Pierson D.M., Ionescu D., Qing G., et al. Pulmonary fibrosis in Hermansky-Pudlak syndrome. a case report and review. Respiration 2006, 73(3):382-395.
66. Lyerla T.A., Rusiniak M.E., Borchers M., et al. Aberrant lung structure, composition, and function in a murine model of Hermansky-Pudlak syndrome. Am J Physiol Lung Cell Mol Physiol 2003, 285(3):L643-L653.
67. Mahavadi P., Korfei M., Henneke I., et al. Epithelial stress and apoptosis underlie Hermansky-Pudlak syndrome-associated interstitial pneumonia. Am J Respir Crit Care Med 2010, 182(2):207-219.
68. Guttentag S.H., Akhtar A., Tao J.Q., et al. Defective surfactant secretion in a mouse model of Hermansky-Pudlak syndrome. Am J Respir Cell Mol Biol 2005, 33(1):14-21.
69. Kerem E., Elstein D., Abrahamov A., et al. Pulmonary function abnormalities in type I Gaucher disease. Eur Respir J 1996, 9(2):340-345.
70. Miller A., Brown L.K., Pastores G.M., et al. Pulmonary involvement in type 1 Gaucher disease: functional and exercise findings in patients with and without clinical interstitial lung disease. Clin Genet 2003, 63(5):368-376.
71. Goitein O., Elstein D., Abrahamov A., et al. Lung involvement and enzyme replacement therapy in Gaucher's disease. QJM 2001, 94(8):407-415.
72. McGovern M.M., Wasserstein M.P., Giugliani R., et al. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 2008, 122(2):e341-e349.
73. Mendelson D.S., Wasserstein M.P., Desnick R.J., et al. Type B Niemann-Pick disease: findings at chest radiography, thin-section CT, and pulmonary function testing. Radiology 2006, 238(1):339-345.
74. Parto K., Svedstrom E., Majurin M.L., et al. Pulmonary manifestations in lysinuric protein intolerance. Chest 1993, 104(4):1176-1182.
75. Deutsch G.H., Young L.R., Deterding R.R., et al. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med 2007, 176(11):1120-1128.
76. Nogee L.M. Genetic basis of children's interstitial lung disease. Pediatr Allergy Immunol Pulmonol 2010, 23(1):15-24.
77. Wert S.E., Whitsett J.A., Nogee L.M. Genetic disorders of surfactant dysfunction. Pediatr Dev Pathol 2009, 12(4):253-274.
78. Suzuki T., Sakagami T., Young L.R., et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010, 182(10):1292-1304.
79. Nogee L.M., de Mello D.E., Dehner L.P., et al. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993, 328(6):406-410.
80. Nogee L.M., Garnier G., Dietz H.C., et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994, 93(4):1860-1863.
81. Andersen C., Ramsay J.A., Nogee L.M., et al. Recurrent familial neonatal deaths: hereditary surfactant protein B deficiency. Am J Perinatol 2000, 17(4):219-224.
82. Somaschini M., Wert S., Mangili G., et al. Hereditary surfactant protein B deficiency resulting from a novel mutation. Intensive Care Med 2000, 26(1):97-100.
83. Wegner D.J., Hertzberg T., Heins H.B., et al. A major deletion in the surfactant protein-B gene causing lethal respiratory distress. Acta Paediatr 2007, 96(4):516-520.
84. Dunbar A.E., Wert S.E., Ikegami M., et al. Prolonged survival in hereditary surfactant protein B (SP-B) deficiency associated with a novel splicing mutation. Pediatr Res 2000, 48(3):275-282.
85. Ballard P.L., Nogee L.M., Beers M.F., et al. Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics 1995, 96(6):1046-1052.
86. Nogee L.M., Dunbar A.E., Wert S.E., et al. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 2001, 344(8):573-579.
87. Thomas A.Q., Lane K., Phillips J., et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 2002, 165(9):1322-1328.
88. Cameron H.S., Somaschini M., Carrera P., et al. A common mutation in the surfactant protein C gene associated with lung disease. J Pediatr 2005, 146(3):370-375.
89. van Moorsel C.H., van Oosterhout M.F., Barlo N.P., et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a Dutch cohort. Am J Respir Crit Care Med 2010, 182(11):1419-1425.
90. Guillot L., Epaud R., Thouvenin G., et al. New surfactant protein C gene mutations associated with diffuse lung disease. J Med Genet 2009, 46(7):490-494.
91. Lawson W.E., Grant S.W., Ambrosini V., et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 2004, 59(11):977-980.
92. Markart P., Ruppert C., Wygrecka M., et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur Respir J 2007, 29(1):134-137.
93. Bridges J.P., Wert S.E., Nogee L.M., et al. Expression of a human surfactant protein C mutation associated with interstitial lung disease disrupts lung development in transgenic mice. J Biol Chem 2003, 278(52):52739-52746.
94. Mulugeta S., Nguyen V., Russo S.J., et al. A surfactant protein C precursor protein BRICHOS domain mutation causes endoplasmic reticulum stress, proteasome dysfunction, and caspase 3 activation. Am J Respir Cell Mol Biol 2005, 32(6):521-530.
95. Mulugeta S., Maguire J.A., Newitt J.L., et al. Misfolded BRICHOS SP-C mutant proteins induce apoptosis via caspase-4- and cytochrome c-related mechanisms. Am J Physiol Lung Cell Mol Physiol 2007, 293(3):L720-L729.
96. Lawson W.E., Cheng D.S., Degryse A.L., et al. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc Natl Acad Sci U S A 2011, 108(26):10562-10567.
97. Weaver T.E. Synthesis, processing and secretion of surfactant proteins B and C. Biochim Biophys Acta 1998, 1408(2-3):173-179.
98. Serrano A.G., Perez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem Phys Lipids 2006, 141(1-2):105-118.
99. Mulugeta S., Gray J.M., Notarfrancesco K.L., et al. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. J Biol Chem 2002, 277(25):22147-22155.
100. Cheong N., Madesh M., Gonzales L.W., et al. Functional and trafficking defects in ATP binding cassette A3 mutants associated with respiratory distress syndrome. J Biol Chem 2006, 281(14):9791-9800.
101. Shulenin S., Nogee L.M., Annilo T., et al. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004, 350(13):1296-1303.
102. Somaschini M., Nogee L.M., Sassi I., et al. Unexplained neonatal respiratory distress due to congenital surfactant deficiency. J Pediatr 2007, 150(6):649-653. 653 e641.
103. Garmany T.H., Wambach J.A., Heins H.B., et al. Population and disease-based prevalence of the common mutations associated with surfactant deficiency. Pediatr Res 2008, 63(6):645-649.
104. Bullard J.E., Wert S.E., Whitsett J.A., et al. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 2005, 172(8):1026-1031.
105. Young L.R., Nogee L.M., Barnett B., et al. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest 2008, 134(1):192-195.
106. Yokota T., Matsumura Y., Ban N., et al. Heterozygous ABCA3 mutation associated with non-fatal evolution of respiratory distress. Eur J Pediatr 2008, 167(6):691-693.
107. Trapnell B.C., Whitsett J.A., Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003, 349(26):2527-2539.
108. Kitamura T., Tanaka N., Watanabe J., et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999, 190(6):875-880.
109. Bonfield T.L., Russell D., Burgess S., et al. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002, 27(4):481-486.
110. Inoue Y., Trapnell B.C., Tazawa R., et al. Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008, 177(7):752-762.
111. Carey B., Trapnell B.C. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010, 135(2):223-235.
112. Uchida K., Nakata K., Trapnell B.C., et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004, 103(3):1089-1098.
113. Uchida K., Beck D.C., Yamamoto T., et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007, 356(6):567-579.
114. Nishinakamura R., Nakayama N., Hirabayashi Y., et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995, 2(3):211-222.
115. Stanley E., Lieschke G.J., Grail D., et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994, 91(12):5592-5596.
116. Suzuki T., Sakagami T., Rubin B.K., et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008, 205(12):2703-2710.
117. Tanaka T., Motoi N., Tsuchihashi Y., et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet 2011, 48(3):205-209.
118. Raghu G., Weycker D., Edelsberg J., et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(7):810-816.
119. Olson A.L., Swigris J.J., Lezotte D.C., et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007, 176(3):277-284.
120. Raghu G., Collard H.R., Egan J.J., et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011, 183(6):788-824.
121. Marshall R.P., Puddicombe A., Cookson W.O., et al. Adult familial cryptogenic fibrosing alveolitis in the United Kingdom. Thorax 2000, 55(2):143-146.
122. Steele M.P., Speer M.C., Loyd J.E., et al. Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med 2005, 172(9):1146-1152.
123. Seibold M.A., Wise A.L., Speer M.C., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 2011, 364(16):1503-1512.
124. Armanios M.Y., Chen J.J., Cogan J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007, 356(13):1317-1326.
125. Tsakiri K.D., Cronkhite J.T., Kuan P.J., et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 2007, 104(18):7552-7557.
126. Cronkhite J.T., Xing C., Raghu G., et al. Telomere shortening in familial and sporadic pulmonary fibrosis. Am J Respir Crit Care Med 2008, 178(7):729-737.
127. Diaz de Leon A., Cronkhite J.T., Katzenstein A.L., et al. Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS One 2010, 5(5):e10680.
128. Wang Y., Kuan P.J., Xing C., et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet 2009, 84(1):52-59.
129. Maitra M., Wang Y., Gerard R.D., et al. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 2010, 285(29):22103-22113.
130. Sosman M.C., Dodd G.D., Jones W.D., et al. The familial occurrence of pulmonary alveolar microlithiasis. Am J Roentgenol Radium Ther Nucl Med 1957, 77(6):947-1012.
131. Ucan E.S., Keyf A.I., Aydilek R., et al. Pulmonary alveolar microlithiasis: review of Turkish reports. Thorax 1993, 48(2):171-173.
132. Castellana G., Lamorgese V. Pulmonary alveolar microlithiasis. World cases and review of the literature. Respiration 2003, 70(5):549-555.
133. Melamed J.W., Sostman H.D., Ravin C.E. Interstitial thickening in pulmonary alveolar microlithiasis: an underappreciated finding. J Thorac Imaging 1994, 9(2):126-128.
134. Helbich T.H., Wojnarovsky C., Wunderbaldinger P., et al. Pulmonary alveolar microlithiasis in children: radiographic and high-resolution CT findings. AJR Am J Roentgenol 1997, 168(1):63-65.
135. Corut A., Senyigit A., Ugur S.A., et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am J Hum Genet 2006, 79(4):650-656.
136. Huqun, Izumi S., Miyazawa H., et al. Mutations in the SLC34A2 gene are associated with pulmonary alveolar microlithiasis. Am J Respir Crit Care Med 2007, 175(3):263-268.
137. Wang H., Yin X., Wu D. Novel human pathological mutations. SLC34A2. Disease: pulmonary alveolar microlithiasis. Hum Genet 2010, 127(4):471.
138. Dogan O.T., Ozsahin S.L., Gul E., et al. A frame-shift mutation in the SLC34A2 gene in three patients with pulmonary alveolar microlithiasis in an inbred family. Intern Med 2010, 49(1):45-49.
139. Ishihara Y., Hagiwara K., Zen K., et al. A case of pulmonary alveolar microlithiasis with an intragenetic deletion in SLC34A2 detected by a genome-wide SNP study. Thorax 2009, 64(4):365-367.
140. Feild J.A., Zhang L., Brun K.A., et al. Cloning and functional characterization of a sodium-dependent phosphate transporter expressed in human lung and small intestine. Biochem Biophys Res Commun 1999, 258(3):578-582.
141. Traebert M., Hattenhauer O., Murer H., et al. Expression of type II Na-P(i) cotransporter in alveolar type II cells. Am J Physiol 1999, 277(5 Pt 1):L868-L873.
142. Hashimoto M., Wang D.Y., Kamo T., et al. Isolation and localization of type IIb Na/Pi cotransporter in the developing rat lung. Am J Pathol 2000, 157(1):21-27.
143. Hunninghake G.W., Costabel U., Ando M., et al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999, 16(2):149-173.
144. Rybicki B.A., Iannuzzi M.C., Frederick M.M., et al. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001, 164(11):2085-2091.
145. Sverrild A., Backer V., Kyvik K.O., et al. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008, 63(10):894-896.
146. Rybicki B.A., Major M., Popovich J., et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 1997, 145(3):234-241.
147. Pietinalho A., Ohmichi M., Hiraga Y., et al. The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients. Sarcoidosis Vasc Diffuse Lung Dis 1996, 13(2):159-166.
148. Schurmann M., Lympany P.A., Reichel P., et al. Familial sarcoidosis is linked to the major histocompatibility complex region. Am J Respir Crit Care Med 2000, 162(3 Pt 1):861-864.
149. Grunewald J. Review: role of genetics in susceptibility and outcome of sarcoidosis. Semin Respir Crit Care Med 2010, 31(4):380-389.
150. Smith G., Brownell I., Sanchez M., et al. Advances in the genetics of sarcoidosis. Clin Genet 2008, 73(5):401-412.
151. den Dunnen J.T., Antonarakis S.E. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat 2000, 15(1):7-12.